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Abstract: Cough is the most common complaint for which patients seek medical attention. Cough variant asthma (CVA) 
is a form of asthma, which presents solely with cough. CVA is one of the most common causes of chronic cough. More 
importantly, 30 to 40% of adult patients with CVA, unless adequately treated, may progress to classic asthma. CVA 
shares a number of pathophysiological features with classic asthma such as atopy, airway hyper-responsiveness, 
eosinophilic airway inflammation and various features of airway remodeling. Inhaled corticosteroids remain the most 
important form of treatment of CVA as they improve cough and reduce the risk of progression to classic asthma most 
likely through their prevention of airway remodeling and chronic airflow obstruction. 
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INTRODUCTION 
  Cough is a very common complaint for which patients 
seek medical attention [1, 2]. A number of guidelines 
defined chronic cough as cough lasting for 8 weeks or longer 
[1, 3-5]. As such, chronic cough can lead to impaired quality 
of life [6]. Asthma is a disease in which the airways narrow 
excessively in response to various stimuli in the presence of 
airway hyper-responsiveness (AHR) and eosinophilic airway 
inflammation. In “classic asthma” (CA) variable airflow 
obstruction typically leads to symptoms such as wheeze, 
dyspnea and cough. In ‘variant asthma’ originally described 
by Glauser in 1972 [7] and subsequently re-named, by 
Corrao et al. [8] as ‘cough variant asthma’ (CVA) cough can 
be the sole presenting symptom. CVA remains one of the 
commonest causes of chronic cough worldwide [2, 9]. More 
importantly, in CA cough may be associated with worse 
prognosis [10-12]. This review article will discuss various 
subtypes of asthma and associated eosinophilic airway 
disorders such as CVA, non-asthmatic eosinophilic 
bronchitis (NAEB); originally termed eosinophilic bronchitis 
without asthma and atopic cough [13-19]. 
COUGH AND ASTHMA 
  Cough is a major symptom of asthma. Cough in asthma 
can be classified into three categories CVA, cough-
predominant asthma and cough that persists despite standard 
therapy with inhaled corticosteroids and bronchodilators [19, 
20]. CVA is a subtype of asthma that usually presents solely 
with cough without any other symptoms such as dyspnea or 
wheezing [8]. In cough-predominant asthma cough is the 
most predominant symptom but other symptoms are also 
present such as dyspnea and/or wheeze [19-21]. These 
symptoms can be elicited on careful clinical history and 
examination. The third subtype is defined as cough that 
persists despite the control of other symptoms such as 
wheeze and breathlessness with standard treatment such as  
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inhaled corticosteroids (ICS) and beta-agonists. There are 
two subtypes in this category. In the first subtype cough is 
responsive to anti-mediator drugs such as leukotriene 
receptor antagonists, histamine H1 receptor antagonists and 
thromboxane synthesis inhibitors or receptor antagonists. 
The inflammatory mediators blocked by these agents are 
likely involved in the development of cough [22, 23]. Cough 
in this subtype is considered a manifestation of asthma, 
which is refractory to ICS and bronchodilators. The other 
subtype is cough due to concomitant conditions such as 
gastroesophageal reflux disease (GERD). Co-existence of 
GERD with asthma or CVA is fairly common, and cough 
may subside with anti-reflux medications [24]. Such 
phenomena may be explained by “cough-reflux self-
perpetuating positive feedback cycle” leading to vicious 
cycle of cough and reflux [25]. As subjective measures of 
cough (cough scores and visual analogue scale) and cough 
reflex sensitivity are poor surrogates for objective cough 
frequency and cough-related quality of life assessment may 
be more appropriate when assessing cough [26]. 
MUCUS HYPER-SECRETION IN ASTHMA AND 
CHRONIC COUGH 
  Cough in asthma is typically dry or minimally 
productive, but it may also be associated with hyper-
secretion of mucus. Mucus hyper-secretion in asthma may be 
potentially related with steeper decline of pulmonary 
function [27]
 and fatal disease [28]. Measurement of secreted 
mucin in sputum has been reported in asthma [29], but not in 
chronic cough, which may involve goblet cell hyperplasia of 
bronchial epithelium with variable sputum production [30, 
31]. We conducted a cross-sectional study to examine mucin 
levels of induced sputum supernatant in 49 patients with CA, 
53 with chronic cough (39 with CVA, 9 with sinobronchial 
syndrome, 5 with GERD) and 11 healthy subjects [32]. 
Sinobronchial syndrome (SBS) was defined as chronic 
sinusitis complicated by neutrophilic inflammation of the 
lower airways [2]. An ELISA method was used [32] to 
detect total levels of various types of airway mucin such as 
MUC5AC and MUC5B [29]. Sputum symptom was semi-
quantified by using a questionnaire. Sputum production was 
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those with GERD and the controls. Whilst all SBS patients 
complained of frequent sputum production, none of the 
GERD patients reported sputum production, resulting in 
statistical differences for these two groups when compared 
with other disease groups (Fig. 1) [32]. Notably, 13 of 39 
CVA patients reported frequent sputum production. This 
may not be a true reflection of the clinical features of CVA, 
because only patients that succeeded with sputum induction 
were enrolled, possible resulting in selection bias [33].
 
However, it is important to notice that a subset of patients 
with CVA presents with productive cough. Sputum mucin 
levels were higher in CA and SBS than in the controls. They 
were also higher in CA than in CVA and GERD, but not 
different among the latter groups and the controls (Fig. 2) 
[32]. When the four disease groups were combined, patients 
with frequent sputum production had greater mucin levels 
than those with occasional or no sputum production, or 
controls (Fig. 3) [32]. These results indicated that the 
difference in mucin levels among subjects reflected the 
degree of mucus hyper-secretion. Interestingly, patients with 
CA showed negative correlations of mucin levels with 
respiratory resistance indices on impulse oscillation [34] and 
with airway sensitivity to methacholine [35], possibly 
indicating protective effects of airway-secreted mucin in 
asthma [32]. 
 
COUGH VARIANT ASTHMA 
  In CVA cough is the sole presenting symptom. CVA is 
characterized by AHR. It responds to bronchodilators such 
as beta-agonists and theophyllines [8, 19, 20]. In Japan, 
CVA remains the most common cause of chronic cough 
followed by SBS, GERD and AC [2, 19, 20, 36-38]. The 
‘health insurance for all’ in Japan allow patients to visit a 
specialist without prior referral from a general practitioner. 
The patients in fact prefer to be assessed by a specialist [2]. 
In the majority of patients with CVA cough can be 
controlled with inhaled corticosteroids. General practitioners 
in Japan are less likely to prescribe inhaled corticosteroids 
than those in Western countries [39]. This may partially 
explain the high prevalence of CVA in Japan. 
ATOPIC FEATURES 
  Seasonal variation of symptom is very common in CVA, 
which may implicate an involvement of atopy. We compared 
74 CVA patients with 115 CA patients with wheezing with 
regard to total and specific IgE levels of 7 common 
aeroallergens [40]. The two groups of asthmatics were 
sensitized to one or more allergens at a similar prevalence 
(60% vs 67%). However, patients with CA had higher total 
IgE, larger numbers of sensitized allergens, and higher rates 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Frequency of sputum symptom in patients with asthma and chronic cough of various causes, who succeeded in sputum induction for 
measurement of mucin in the supernatant (ref. [32]). CVA=cough variant asthma; SBS=sinobronchial syndrome; GERD=gastroesophageal 
reflux disease. Cough and Asthma  Current Respiratory Medicine Reviews, 2011, Vol. 7, No. 1      49 
of sensitization to a number of allergens than did patients 
with CVA. The results revealed no specific antigen of CVA 
with higher sensitization rate than CA [40]. A literature 
review indicates that the prevalence of atopy in CVA, as 
defined by the presence of at least one positive serum 
specific IgE or skin test response to common aeroallergens, 
ranges from 40 to 80% [16, 17, 32, 40-44]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Induced sputum levels of muciun in patients with asthma 
and chronic cough (ref. [32]). 
PHYSIOLOGICAL FEATURES 
  Pulmonary function tests of CVA patients show normal 
to near normal results of peak expiratory flow (PEF) or 
FEV1, but when compared with healthy subjects or patients 
with post-infectious cough, these values may be slightly but 
significantly lower [41]. Mild diurnal change of PEF or its 
fluctuation in parallel with coughing may be observed [45], 
but to a lesser degree than that seen in CA. Reversibility of 
FEV1 with beta-agonist is smaller in CVA than in CA, 
because baseline FEV1 values are normal or nearly normal in 
the majority of CVA patients. In addition to these facts, 
CVA is the only cause of chronic cough that is responsive to 
bronchodilators [5, 46]. It is thus suggested that coughing of 
CVA may be due to bronchoconstriction, but the detailed 
causal relationship involved in cough and broncho-
constriction remains unknown. A recent animal experiment 
has suggested that cough due to bronchoconstriction is 
mediated  via  rapidly adapting receptors, but not C fibers 
[47]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Sputum mucin levels in patients of all disease groups 
reclassified according to their frequency of sputum production and 
in controls (ref. [32]). 
  AHR of CVA patients has been considered similar to or 
milder than that of CA patients. In adult CVA patients, 
airway sensitivity (threshold dose of methacholine to 
increase respiratory resistance) and airway reactivity (slope 
of methacholine - respiratory resistance dose response curve) 
of a tidal breathing method [35] were both smaller than in 
CA patients [48]. In children, only airway reactivity was 
smaller in CVA patients than in CA patients [49], possibly 
explaining the absence of wheezing in CVA. As a whole, the 
physiological abnormalities of CVA are more modest than 
those of CA. However, this does not mean that CVA is a 
milder form of asthma, because CVA patients are often more 
difficult to manage than CA patients who predominately 
present with wheeze. Cough receptor sensitivity, most 
commonly assessed by inhalation of capsaicin, may or may 
not be heightened in CVA as compared with healthy 
controls, and may decrease with treatment with leukotriene 
receptor antagonists [50] while remain unchanged with ICS 
treatment [51]. This might be associated with excellent anti-
tussive effect of the former class of drugs [52], but the 
details of its mechanism remain unknown. 
PATHOLOGICAL FEATURES 
  In patients with CVA, eosinophils are increased in the 
sputum [51, 53], bronchoalveolar lavage (BAL) fluid and 
bronchial mucosal tissue [41]. The magnitude of this   
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increase correlates with the severity of disease as defined by 
symptom and treatment required to achieve control [41]. For 
biopsy specimens of central airway mucosa and BAL fluid 
recovered from peripheral airways and lung parenchyma, the 
degree of eosinophilia is similar between CA and CVA, 
indicating a similarity in the site of inflammation [41]. One 
study showed an increase of neutrophils as well as 
eosinophils in the airway mucosa of CVA patients (Fig. 4) 
[30], and such concomitant increase of both cells may lead to 
more severe disease characterized by refractoriness to 
treatment with ICS [54]. Mast cells, an important source of 
tussive as well as fibrogenic mediators, was increased in the 
airway mucosa of non-asthmatic chronic cough patients but 
not CVA patients (Fig. 4) [30]. 
  Similar to asthma, in CVA structural changes such as 
sub-epithelial thickening, goblet cell hyperplasia and 
vascular proliferation have been demonstrated on mucosal 
biopsies [30, 55, 56]. These changes may be secondary to 
airway inflammation. Pathophysiological significance of 
these changes has been indicated in asthma, and early anti-
inflammatory treatment is also recommended in CVA. 
However, they may also be a consequence of long-term 
mechanical stimulation by coughing [30, 56, 57], because 
most of these changes are also present in subjects with non-
asthmatic chronic cough [30, 56]. Increased inflammatory 
mediators (e.g. histamine, prostaglandins D2 and E2 and 
leukotrienes C4, D4 and E4) [23], increased expression of 
capsaicin receptor TRPV-1 [58], and decreased pH of airway 
lining fluid that may activate TRPV-1 [59] may play a role 
in the development of cough. One study showed a similar 
pattern of sputum markers (cellular and humoral) between 
CA and CVA [60]. A computed tomography (CT) study has 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Number of eosinophils, neutrophiils and mast cells in the submucosa of bronchial biopsy specimens obtained from patients with 
CVA (n=14), those with non-asthmatic chronic cough (n=33; 6 with postnasal drip/rhinitis, 5 with GERD, 3 with bronchiectasis, and 19 with 
idiopathic disease) and 15 healthy subjects [30]. Cough and Asthma  Current Respiratory Medicine Reviews, 2011, Vol. 7, No. 1      51 
revealed airway wall thickening, a feature of CA [61], in 
patients with CVA (Fig. 5a, b) [42]. This may reflect the net 
effect of airway remodeling features discussed above. 
However, airway wall thickening is also present in patients 
with non-asthmatic chronic cough although to a lesser degree 
(Fig. 5b) [42], which is consistent with the biopsy studies 
[30, 56]. 
DIAGNOSIS 
  CVA is characterized by AHR and responsiveness to 
bronchodilators, but the presence of AHR is only consistent 
with, but not diagnostic of, CVA [46]. Improvement of 
cough with bronchodilators such as beta-agonists is the 
essential diagnostic feature of CVA, as demonstrated by the 
double-blind controlled study by Irwin et al. [46]. Based on 
these features, the Japanese Respiratory Society cough 
guideline considers responsiveness to bronchodilators as the 
key diagnostic feature of CVA [5]. Sputum eosinophilia 
suggests a diagnosis of CVA [51, 53], as well as AC or 
NAEB. However, only 30% of CVA patients fulfill the 
criteria of sputum eosinophilia as defined by >3% of 
leukocytes [14] in our experience (unpublished data), and its 
absence does not exclude the diagnosis of CVA. Exhaled NO 
levels may also be elevated and useful in the diagnosis of 
CVA [62]. 
TREATMENT AND PROGNOSIS 
  After the diagnosis is established, treatment of CVA is 
essentially the same as in CA [5]. Bronchodilators (short-
acting inhaled 2 agonists or theophyllines) may be used 
especially in patients with intermittent cough. However, as in 
CA eosinophilic airway inflammation and remodeling are 
present in CVA, ICS are the first line treatment in CVA 
especially in those patients who have persistent cough [30, 
41, 55, 56]. There are no data currently available regarding 
the choice of
  ICS, its dose or duration that should be used 
for the treatment
 of CVA [3, 52, 63]. If ICS mono-therapy is 
insufficient, other agents can be added such as long-acting 2 
agonists, slow-release theophylline, or leukotriene receptor 
antagonists [5]. Effectiveness of mono-therapy with 
leukotriene receptor antagonists has been reported possibly 
through its anti-inflammatory effects [50, 64]. Occasionally, 
(a) 
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Fig. (5). Airway wall thickening in patients with CVA (n=27) and non-asthmatic chronic cough (n=26; 8 with SBS, 3 with GERD, 3 with 
post-infective cough, 11 with unexplained cough, and 1 with combined SBS and GERD), as indicate by helical CT scans of right apical 
upper lobe bronchus (a). Airway wall thickness (wall area/body surface area) as quantified by automatic analysis shows that airway walls of 
patients are thickened as compared with healthy subjects (n=15), to a greater degree in patients with CVA (b) [42]. 52    Current Respiratory Medicine Reviews, 2011, Vol. 7, No. 1  Akio Niimi 
for acute exacerbations of CVA, a short-course of oral 
corticosteroids may be required. A subset of patients with 
CVA can develop wheeze and progresses to CA. If ICS are 
not used in CVA, the progression rate to CA has been 
reported between 30 to 40% [17, 43]. Factors that may 
predict the development of CA include AHR [17] and 
exaggerated maximal airway response to methacholine, 
sputum eosinophilia [65], and sensitization to allergens [40]. 
Early ICS treatment may reduce the risk of progression to 
CA [17, 43]. Avoidance of relevant allergens might also be 
important [40]. As in CA cough in CVA often re-occurs if 
treatment is discontinued [43]. 
  Annual changes of FEV1 have been reported to be similar 
among patients with CVA (-29 ml/year by average), those with 
AC (-21 ml/year) and healthy subjects (-28 ml/yr). Values for 
CVA patients ranged from approximately -90 ml to +30 ml 
[18]. In our 3- year follow-up [19], annual changes of FEV1 
were -2 ± 36 ml in 7 patients with mild CVA (coughing 
episodes interfering with usual activities or sleep 3 times or less 
yearly), and -62 ± 35 ml in 4 patients with difficult-to-control 
disease (4 or more such episodes yearly)(p=0.014). The 
difficult-to-control group was treated with higher doses of ICS 
than the mild group, reflecting their severity [19]. Although this 
is a small study, these results may be consistent with recent 
studies in CA that showed a positive relationship between the 
number of asthma exacerbations and progressive loss of FEV1 
[66]. 
DISORDERS RELATED TO CVA 
  Atopic cough as proposed by Fujimura et al. [16-18, 44, 51] 
presents with bronchodilator-resistant dry cough associated with 
an atopic constitution. It is characterized by eosinophilic 
tracheobronchitis and cough hypersensitivity. However, there is 
absence of AHR and variable airflow obstruction. AC usually 
responds to ICS treatment. These features are shared by NAEB 
[13-15, 53]. However, AC lacks BAL eosinophilia [16]. Unlike 
CVA [17, 41, 43, 44] and NAEB [19, 67, 68], AC rarely 
progresses to CA with wheezing [17]. Histamine H1 antagonists 
are effective in AC [69], but their efficacy in NAEB is 
unknown. The involvement of airway remodeling and 
accelerated decline of lung funciton, which has been shown in 
CVA [19, 30, 42, 55] and NAEB [15, 70, 71], is unknown for 
AC. NAEB thus significantly overlaps with AC, but might also 
include milder cases of CVA with very modest AHR. The 
clinical and pathological features of eosinophilic airway 
disorders including CA are summarized in Table 1. The 
confusion, or lack of consensus, in these related entities may be 
affecting the etiology of chronic cough reported from various 
countries [2, 19]. 
CONCLUSIONS 
  CVA is one of the most common causes of chronic cough. 
CVA therefore should be considered in patients presenting with 
persistent cough. The role of inhaled corticosteroids in CVA is 
very important. The inhaled corticosteroids not only control 
cough in CVA but also they may prevent the development of 
wheeze, airway remodeling and chronic airflow obstruction. 
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